Inhibition of highly pathogenic avian H5N1 influenza virus propagation by RNA oligonucleotides targeting the PB2 gene in combination with celecoxib

Journal of Gene Medicine

Volumn 13, Issue 4, 2011, Pages 243-249

  Jin, Yi ^a   Zhang, Guozhong ^a   Hu, Yanxin ^a   Ding, Meng ^a   Li, Yi ^a   Cao, Shanpin ^a   Xue, Jia ^a   Sun, Lun Quan ^b,c   Wang, Ming ^a  

^a CHINA AGRICULTURAL UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

Antisense oligonucleotides; Celecoxib; HPAIV H5N1; PB2

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CELECOXIB; COMPLEMENTARY RNA; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AVIAN INFLUENZA VIRUS; CELL STRAIN; CONTROLLED STUDY; FEMALE; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; POLYMERASE BASIC PROTEIN 2 GENE; PRIORITY JOURNAL; PROTEIN SECRETION; SURVIVAL; VIRUS EXPRESSION; VIRUS GENE; VIRUS INHIBITION; VIRUS LOAD; VIRUS PLAQUE; VIRUS REPLICATION;

ANIMALS; CELL LINE; CHICKENS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; FEMALE; GENE TARGETING; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; LETHAL DOSE 50; MICE; MICE, INBRED BALB C; OLIGONUCLEOTIDES; POLYMERASE CHAIN REACTION; PYRAZOLES; RNA REPLICASE; SULFONAMIDES; TRANSFECTION; VIRAL PROTEINS; VIRUS REPLICATION;

ANIMALIA; AVES; AVIAN INFLUENZA VIRUS; MUS; ORTHOMYXOVIRIDAE;

EID: 79955148033     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1558     Document Type: Article

References (21)

1. Claas EC, Osterhaus AD, Beek RV, et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998; 351: 472-477.
2. Shortridge KF, Zhou NN, Guan Y, et al. Characterization of avian H5N1 influenza viruses from poultry in Hong Kong. Virology 1998; 252: 331-342.
3. Palese P. Influenza: Ole and new threats. Nature Med 2004; 10: S82-S87.
4. Korteweg C, Gu J. Pathology, molecular biology, and pathogenesis of avian influenza A (H5N1) infection in humans. Am J Pathol 2008; 172: 1155-1170.
5. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12: 1203-1207.
6. Salomon R, Hoffmann E, Webster RG. Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection. Proc Natl Acad Sci USA 2007; 104: 12479-12481.
7. Carter MJ. A rationale for using steroids in the treatment of severe cases of H5N1 avian influenza. J Med Microbiol 2007; 56: 875-883.
8. Spurgers KB, Sharkey CM, Warfield KL, et al. Oligonucleotide antiviral therapeutics: antisense and RNA interference for highly pathogenic RNA viruses. Antiviral Res 2008; 78: 26-36.
9. Mizuta T, Fujiwara M, Abe T, et al. Inhibitory effects of an antisense oligonucleotide in an experimentally infected mouse model of influenza A virus. Biochem Biophys Res Commun 2000; 279: 158-161.
10. Wu Y, Zhang G, Li Y, et al. Inhibition of highly pathogenic avian H5N1 influenza virus replication by RNA oligonucleotides targeting NS1 gene. Biochem Biophys Res Commun 2008; 365: 369-374.
11. Evseenko VA, Bukin EK, Zaykovskaya AV, et al. Experimental infection of H5N1 HPAI in BALB/c mice. Virol J 2007; 4: 77.
12. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-delta delta C (T)) method. Methods 2001; 25: 402-408.
13. Sandbulte MR, Jimenez GS, Boon AC, et al. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 2007; 4: e59.
14. McKimm-Breschkin JL, Selleck PW, Usman TB, et al. Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg Infect Dis 2007; 13: 1354-1357.
15. Cheung CL, Rayner JM, Smith GJ, et al. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J Infect Dis 2006; 193: 1626-1629.
16. De Jong MD, Tran TT, Truong HK, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353: 2667-2672.
17. Cheung CY, Poon LL, Lau AS, et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002; 360: 1831-1837.
18. Szretter KJ, Gangappa S, Lu X, et al. Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice. J Virol 2007; 81: 2736-2744.
19. Chan MC, Cheung CY, Chui WH, et al. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir Res 2005; 6: 135.
20. Rainsford KD. Influenza ('Bird Flu'), inflammation and anti-inflammatory/analgesic drugs. Inflammopharmacology 2006; 14: 2-9.
21. Bo-Jian Z, Kwok-Wah C, Yong-Ping L, et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci USA 2008; 105: 8091-8096.